| Autor: |
Rocha de Almeida, Rebeca, Aidar, Felipe J., Cândido de Souza, Márcia Ferreira, Batista Oliveira, Victor, Menezes Oliveira, Joselina Luzia, Baumworcel, Leonardo, Costa Pereira, Larissa Monteiro, Santana Mendonça de Oliveira, Larissa Marina, Oliveira Costa, Jamille, Santos Rocha, Raysa Manuelle, Soares Barreto-Filho, José Augusto, Borba Neves, Eduardo, Díaz-de-Durana, Alfonso López, Santos Silva, José Rodrigo, Antonio Almeida-Santos, Marcos, Sobral Sousa, Antônio Carlos |
| Předmět: |
|
| Zdroj: |
Medicina (1010660X); Sep2021, Vol. 57 Issue 9, p1-16, 16p |
| Abstrakt: |
Background and Objectives: In severe obesity, a relevant weight loss can promote the reduction of comorbidities, such as systemic arterial hypertension (SAH), dyslipidemia, and diabetes mellitus (DM2). Bariatric surgery (BS) has been an essential resource in the therapy of this disease with a short-term reduction of cardiometabolic risk (CR). This study aimed to evaluate the reduction of factors associated with the CR in patients undergoing BS at a 5-year follow-up. Materials and Methods: This is a longitudinal, retrospective study carried out with patients undergoing BS by the Brazilian Public Healthcare System (PHS). Anthropometric and clinical parameters related to the CR (DM2, dyslipidemia, and SAH), quantified by the Assessment of Obesity-Related Comorbidities (AORC) score, were evaluated at the following moments: admission and preoperative and postoperative returns (3 months, 6 months, 1 to 5 years). Results: The sample had a mean age of 44.69 ±9.49 years and were predominantly in the age group 20–29 years (34.80%) and women (72.46%). At admission to the service, 42.3% had DM2, 50.7% dyslipidemia, and 78.9% SAH. Regarding BS, the gastric bypass technique was used in 92.86% of the sample, and the waiting time for the procedure was 28.3 ±24.4 months. In the pre- and postoperative period of 3 months, there was a significant reduction in the frequency of DM2 (p < 0.003), dyslipidemia (p < 0.000), and SAH (p < 0.000). However, at postoperative follow-up from 6 months to 5 years, there was no significant reduction in the comorbidities studied. After five years, 35.7% had total remission of DM2 and 2.9% partial remission of DM2, 44.2% had control and remission of dyslipidemia, and 19.6% of SAH (AORC score ≤2 for the comorbidities). Conclusion: BS promoted a reduction of the CR in the first three months after BS in severely obese PHS users. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
